- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04193020
Acute and Chronic Inflammatory Disease, Lifestyle and Treatment Response (ACID LTR)
Impact of Lifestyle and Treatment on the Recurrency and Severity of Acute and Chronic Inflamatory Eye Diseases: Protocol on Prospective Cohort Study
Acute and chronic inflammatory eye diseases are difficult to diagnose and maintain quiescent with therapy. Proposed study is aimed to find on the one hand, novel factors for recurrence of the disease or remission of inflammation and evaluation of the impact of lifestyle and known factors on the other.
Each patient is treated in accordance to the best of medical knowledge and guidelines for each disease.
This prospective cohort study will enroll uveitic patients to the steroid only group (SG), combined (steroid and adjuvant drug) group (CG) or bilogic therapy group (BTG).
At baseline, patient data are recorded using patient-reported outcome measures and clinical assessments (ophthalomology) on disease activity (clinical scales), quality of life, and lifestyle together with registry data on comorbidity and medication. During follow-up evaluation of a successful treatment outcome response will be based on clinical scales and most frequently used primary endpoints; the major outcome of the analyses will be to detect differences in treatment outcome between patients in different treatment group.
연구 개요
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: Joanna Przeździecka-Dołyk, PhD
- 전화번호: +49605693022
- 이메일: joanna.przezdziecka-dolyk@umed.wroc.pl
연구 장소
-
-
-
Wrocław, 폴란드, 54-622
- 모병
- Department of Ophthalmology
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- new diagnosis of uni or bilateral uveitis
- recurrence of the diagnosed previously uni or bilateral uveitis
Exclusion Criteria:
- not mentally able to reply the questionnaire
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
steroid only group (SG)
|
Surveillance card and additional examination to find novel markers and better assess the existing ones
|
combined (steroid and adjuvant drug) group (CG)
|
Surveillance card and additional examination to find novel markers and better assess the existing ones
|
bilogic therapy group (BTG)
|
Surveillance card and additional examination to find novel markers and better assess the existing ones
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Treatment success
기간: 1 year
|
Total number of treatment success in each group
|
1 year
|
Recurrence time
기간: 10 years
|
Time to the next recurrence after the treatment regimen introduction
|
10 years
|
Severe visual loss
기간: 10 years
|
Time and cause of severe visual loss
|
10 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
ETDRS Visual Acuity
기간: 10 years
|
Visual Acuity will be performed with ETDRS charts different for right and left eye
|
10 years
|
The SUN working group grading system for anterior chamber cells
기간: 10 years
|
At each visit anterior chamber will be examined to assess anterior chamber cells (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°).
The recorded number of cells will be used to determine the grade according to the SUN criteria.
|
10 years
|
The SUN working group grading system for anterior chamber flare
기간: 10 years
|
At each visit anterior chamber will be examined to assess anterior chamber flare (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°).
The observed changes will be used to determine the grade according to the SUN criteria.
|
10 years
|
AREDS 2008 Clinical Lens Opacity Grading Procedure
기간: 10 years
|
Using AREDS system for classifying cataracts from photographs: AREDS Report No. 4 the lens opacity will be graded.
|
10 years
|
NIH grading system for vitreous cells
기간: 10 years
|
At each visit vitreous will be examined to assess vitreous cells (1mm x 3mm slit beam in anterior vitreous).
The recorded number of cells will be used to determine the grade according to the NIH criteria.
|
10 years
|
NIH grading system for vitreous haze
기간: 10 years
|
At each visit vitreous will be examined to assess vitreous haze.
The recorded of clarity of posterior pole funduscopy will be used to determine the grade according to the NIH criteria.
|
10 years
|
Submacular choroidal thickness
기간: 10 years
|
OCT EDI recordings processed with developed by researchers methodology for image processing.
|
10 years
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
COVID-19 confirmed infection asymptomatic patient
기간: 1 year
|
PCR-positive result of COVID-19 specific testing, no treatment required
|
1 year
|
COVID-19 confirmed infection
기간: 1 year
|
PCR-positive result of COVID-19 specific testing, patient require treatment.
The mode of treatment will be recorded into several groups: 1) antibiotics, 2) antivirals, 3) biologic treatment, 4) immunoglobulins, 5) steroids
|
1 year
|
COVID-19 related acute respiratory distress syndrome (ARDS)
기간: 1 year
|
COVID-19 related acute respiratory distress syndrome (ARDS).
Situation in which patients need any of described below: 1) supportive oxygen therapy, 2) non-invasive ventilation, 3) invasive/ mechanical ventilation, 4) use of ECMO, 5) admission to intensive care unit, 6) dialysis
|
1 year
|
Ocular Surface Disease Index
기간: 1 year
|
Ocular Surface Disease Index (OSDI) questionaire results are used to define if during the course of the disease the dry eye syndrom occurs.
Used with subclasses describing the vision-related functions, ocular symptoms, environmental triggers
|
1 year
|
Dry Eye Questionnaire
기간: 1 year
|
Dry Eye Questionnaire (DEQ 5) questionaire results are used to define if during the course of the disease the dry eye syndrom occurs.
Used with subscales describing the eye dyscomfort, eye dryness and watery eyes.
|
1 year
|
SANDE Questionnaire
기간: 1 year
|
SANDE Questionnaire that assess the frequency and severity of symptoms during the treatment.
|
1 year
|
LIKERT Questionnaire
기간: 1 year
|
LIKER Questionnaire that assess the frequency, severity of symptoms and infuence of symptoms on the patient day-to-day activities during the treatment.
|
1 year
|
LIPCOF scale
기간: 1 year
|
Assesment of conjunctival folds according to pre-defined scale.
|
1 year
|
OXFORD scale
기간: 1 year
|
OXFORD scale conducted with instalation of 2 microliters of 2% fluorescite into the conjunctival sac and assessment according to the pre-defined scale.
The subscales for nasal, temporal and lower lid conjunctiva as well as for cornea was used.
The scale has been conducted during the treatment period and if necessary during additional visits.
|
1 year
|
SICCA scale
기간: 1 year
|
SICCA scale conducted with instalation of 2 microliters of 2% fluorescite into the conjunctival sac and assessment of cornea according to the pre-defined scale.
Different dye was used for conjunctica (lizamine green).
The subscales for nasal and temporal conjunctiva as well as for cornea was used.
The scale has been conducted during the treatment period and if necessary during additional visits.
|
1 year
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Surveillance card에 대한 임상 시험
-
Boston Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
University College, London완전한
-
Ottawa Hospital Research InstituteThe Hospital for Sick Children; University of Ottawa; Children's Hospital of Eastern Ontario 그리고 다른 협력자들알려지지 않은
-
ER/LA Opioid REMS Program Companies (RPC)알려지지 않은약물 남용 | 오피오이드 관련 장애 | 마약 남용 | 오피오이드 중독